<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - GABAPENTIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>GABAPENTIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#effectOnLaboratoryTests" data-toggle="tab">Effect on laboratory tests</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive treatment of focal seizures with or without secondary generalisation</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 300 mg once daily for day 1, then 300 mg twice daily for day 2, then 300 mg 3 times a day for day 3, alternatively initially 300 mg 3 times a day for day 1, then increased in steps of 300 mg every 2&#8211;3 days in 3 divided doses, adjusted according to response; usual dose 0.9&#8211;3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day), some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                10 mg/kg once daily (max. per dose 300 mg) for day 1, then 10 mg/kg twice daily (max. per dose 300 mg) for day 2, then 10 mg/kg 3 times a day (max. per dose 300 mg) for day 3; usual dose 25&#8211;35 mg/kg daily in 3 divided doses, daily dose maximum to be given in 3 divided doses, some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate; maximum 70 mg/kg per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 300 mg once daily for day 1, then 300 mg twice daily for day 2, then 300 mg 3 times a day for day 3, alternatively initially 300 mg 3 times a day for day 1, then increased in steps of 300 mg every 2&#8211;3 days in 3 divided doses, adjusted according to response; usual dose 0.9&#8211;3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day), some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Monotherapy for focal seizures with or without secondary generalisation</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 300 mg once daily for day 1, then 300 mg twice daily for day 2, then 300 mg 3 times a day for day 3, alternatively initially 300 mg 3 times a day for day 1, then increased in steps of 300 mg every 2&#8211;3 days in 3 divided doses, adjusted according to response; usual dose 0.9&#8211;3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day), some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 300 mg once daily for day 1, then 300 mg twice daily for day 2, then 300 mg 3 times a day for day 3, alternatively initially 300 mg 3 times a day for day 1, then increased in steps of 300 mg every 2&#8211;3 days in 3 divided doses, adjusted according to response; usual dose 0.9&#8211;3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day), some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Neuropathic pain</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 300 mg once daily for day 1, then 300 mg twice daily for day 2, then 300 mg 3 times a day for day 3, alternatively initially 300 mg 3 times a day for day 1, then increased in steps of 300 mg every 2&#8211;3 days in 3 divided doses, adjusted according to response; maximum 3.6 g per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Migraine prophylaxis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 300 mg daily, then increased to up to 2.4 g daily in divided doses, adjusted according to response.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>





      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Reduce dose to 0.6&#8211;1.8&#8239;g daily in 3 divided doses if eGFR 50&#8211;80&#8239;mL/minute/1.73&#8239;m<sup>2</sup>. </p><p>Reduce dose to 300&#8211;900&#8239;mg daily in 3 divided doses if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>Reduce dose to 300&#8239;mg on alternate days (up to max. 600&#8239;mg daily) in 3 divided doses if eGFR 15&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>. </p><p>Reduce dose to 300&#8239;mg on alternate days (up to max.300&#8239;mg daily) in 3 divided doses if eGFR less than 15&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;consult product literature.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Reduce dose if estimated glomerular filtration rate less than 80&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; consult product literature.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, abnormal reflexes, abnormal thoughts, acne, amnesia, anorexia, anxiety, arthralgia, ataxia, confusion, constipation, convulsions, cough, depression, diarrhoea, dizziness, drowsiness, dry mouth, dry throat, dyspepsia, dyspnoea, emotional lability, fever, flatulence, flu syndrome, gingivitis, headache, hostility, hypertension, impotence, increased appetite, insomnia, leucopenia, malaise, movement disorders, myalgia, nausea, nervousness, nystagmus, oedema, paraesthesia, pharyngitis in adults, pruritus, rash, rhinitis, speech disorder, tremor, twitching, vasodilatation, vertigo, visual disturbances, vomiting, weight gain,
              </p>
              <p>
                <strong>uncommon:</strong> Palpitations,
              </p>
              <p>
                <strong>notKnown:</strong> Acute renal failure, alopecia, blood glucose fluctuations in patients with diabetes, breast hypertrophy, gynaecomastia, hallucinations, hepatitis, hypersensitivity syndrome, incontinence, pancreatitis, Stevens-Johnson syndrome, suicidal ideation, thrombocytopenia, tinnitus,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">In children</h3>
              <p>Capsules can be opened but the bitter taste is difficult to mask.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Gabapentin for neuropathic pain</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/gabapentin-for-neuropathic-pain">www.medicinesforchildren.org.uk/gabapentin-for-neuropathic-pain</xref>
            </p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Gabapentin for preventing seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/gabapentin-for-preventing-seizures">www.medicinesforchildren.org.uk/gabapentin-for-preventing-seizures</xref>
            </p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <p>The levels of propylene glycol, acesulfame K and saccharin sodium may exceed the recommended WHO daily intake limits if high doses of gabapentin oral solution (Rosemont brand) are given to adolescents or adults with low body-weight (39&#8211;50&#8239;kg)&#8212;consult product literature.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Diabetes mellitus
          </li>
          <li>
              <strong>:</strong>
            elderly in adults
          </li>
          <li>
            high doses of oral solution in adolescents and adults with low body-weight
          </li>
          <li>
            history of psychotic illness
          </li>
          <li>
            mixed seizures (including absences)
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in children under 6 years.</p><p>Not licensed at doses over 50&#8239;mg/kg daily in children under 12 years.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In adults</h3>
              <p>Not licensed for migraine prophylaxis.</p>
            </section>
      </section>






      <section class="tab-pane" id="effectOnLaboratoryTests">
        <h2>Effect on laboratory tests</h2>

            <section class="effectOnLaboratoryTests">
              <p>False positive readings with some urinary protein tests.</p>
            </section>
      </section>




      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of GABAPENTIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,
            gel,

            <div id="PHP76441"><a href="../medicinalForm/PHP76441.html" data-target="#PHP76441" data-action="load">Tablet</a></div>
            <div id="PHP76448"><a href="../medicinalForm/PHP76448.html" data-target="#PHP76448" data-action="load">Capsule</a></div>
            <div id="PHP76459"><a href="../medicinalForm/PHP76459.html" data-target="#PHP76459" data-action="load">Oral solution</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
